Resources

This report describes a pilot project that PATH conducted in the Afar Region of Ethiopia that aimed to increase vaccination coverage through social mobilization committees and communication activities. It examines the challenges to achieving vaccination coverage in the region, provides success stories demonstrating behavior change, and best practices and lessons learned.

As part of PATH’s work in vaccine and pharmaceutical technologies, this technology update highlights our work in microarray patches (also known as microneedle patches) for vaccine delivery. It explores the advantages of delivering vaccines by microarray patch including the potential for increased thermostability, ease of use, and safety. A related technology update captures our work in microarray patches for drug delivery.

As part of PATH’s work in vaccine and pharmaceutical technologies, this technology update highlights our work in microarray patches (also known as microneedle patches) for drug delivery. It explores the advantages of delivering drugs by microarray patch including the potential for increased patient compliance and safety. A related technology update captures our work in microarray patches for vaccine delivery.

This publication presents highlights from the 20-year story of PATH and its partners who developed, validated, and are introducing SILCS—the first new diaphragm in 50 years. Marketed by Kessel medintim GmbH as the Caya® contoured diaphragm—SILCS is expanding women’s options for nonhormonal contraception in developed and developing countries. Cette publication retrace les faits marquants de la collaboration entre PATH et ses partenaires ces vingt dernières années afin de développer, valider, fabriquer, mettre sur le marché et distribuer le premier nouveau diaphragme au monde depuis 50 ans.Commercialisé par Kessel medintim GmbH sous le nom diaphragme Caya® à rebords, le diaphragme SILCS permet d’élargir les options faites aux femmes en termes de santé reproductive dans les pays développés et en développement.

During the past 25 years, Zambia has made tremendous progress in preventing deaths and improving health among women, newborns, and children. Despite this, many still do not receive basic health services and lack access to essential medicines, products, and technologies. This report demonstrates the potential impact of increased prioritization of reproductive, maternal, newborn, and child health commodities and interventions in order to support advocates as they interact with decision-makers to influence policy and budget changes.